Skip to main content
NewslettersWatchlist

Telesis Bio Inc(TBIO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.3121
Day High0.3301
Open:0.3285
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
GlobeNewswire
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
GlobeNewswire
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
GlobeNewswire
Telesis Bio Appoints William J. Kullback Chief Financial Officer
GlobeNewswire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
GlobeNewswire
Telesis Bio to Present at Jefferies Healthcare Conference 2023
GlobeNewswire
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
GlobeNewswire
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock
Globe NewsWire
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGRF, SIC, SAFM, TBIO; Shareholders are Encouraged to Contact the Firm
Globe NewsWire
INVESTIGATION: Halper Sadeh LLP Investigates CMO, TBIO, SIC, SAFM; Shareholders are Encouraged to Contact the Firm
Globe NewsWire
INVESTIGATION: Halper Sadeh LLP Investigates SAFM, SBKK, SQ, TBIO; Shareholders are Encouraged to Contact the Firm
Globe NewsWire
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates SQ, TBIO, OSBC, IKNX; Shareholders are Encouraged to Contact the Firm
Globe NewsWire
Lifshitz Law Firm, P.C. Announces Investigation of HFC, OSBC, RYFL and TBIO
Business Wire
TRANSLATE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Translate Bio - TBIO
Globe NewsWire
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Translate Bio, Inc. Merger
Globe NewsWire
TRANSLATE BIO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TBIO and Encourages Investors to Contact the Firm
Business Wire
Translate Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Translate Bio, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TBIO
Globe NewsWire
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
Globe NewsWire
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
Globe NewsWire
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
Globe NewsWire
Translate Bio to Participate in Upcoming Investor Conferences
Globe NewsWire
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
Globe NewsWire
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
Globe NewsWire
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines

Profile

Telesis Bio is an automated multi-omic and synthetic biology solutions company. Its BioXp(R) system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. Telesis Bio, formerly known as Codex DNA Inc., is based in SAN DIEGO.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.